Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

The Anatomy of a Mispriced Biotech: Why Mesoblast’s $14 Capitulation is a Screaming Buy

2026-03-24BullishStrongChange from report: -4.0%1M: +8.3%3M: +8.6%

Mesoblast's $14 stock price is a mispriced opportunity. A key insider bought out toxic debt, provided cheap financing, and invested $16M in shares. The company is now commercial with strong revenue growth, not a speculative cash burn.